循环免疫细胞与阿尔茨海默病风险之间的因果关系:孟德尔的随机化研究
Hua Xue1, Jiajia Chen2, Li Zeng3
1Department of Neurology, Sichuan Taikang Hospital, Chengdu, Sichuan, China.
Experimental gerontology
|February 1, 2024
概括
这项研究使用门德尔的随机化方法将七种免疫细胞表型与阿尔茨海默病 (AD) 风险联系起来. 这些发现为AD的生物机制和潜在的早期治疗目标提供了新的见解.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
背景情况:
- 越来越多的证据表明免疫细胞与阿尔茨海默病 (AD) 之间存在联系.
- 了解这种联系对于开发有效的AD治疗至关重要.
研究的目的:
- 通过全面的双样本孟德尔随机化 (MR) 分析,研究731种免疫细胞特征与阿尔茨海默病 (AD) 之间的因果关系.
- 为了确定可能因果关系地影响AD风险的特定免疫表型.
主要方法:
- 利用公开可用的全基因组协会研究 (GWAS) 数据对731个免疫细胞特征和AD.
- 采用逆方差加权 (IVW) 方法作为主要的MR分析技术.
- 进行了敏感性分析,以确保研究结果的稳定性,异质性和水平向性.
主要成果:
- 在FDR调整后确定了七种与AD风险显著相关的免疫表型.
- 具体的关联包括HLA DR在CD33-HLA DR+,分泌Treg%CD4,HLA DR+T细胞AC,激活和休息Treg%CD4 Treg,CD33在CD33dim HLA DR+CD11b+,CD33在CD14+单细胞上,CD33在CD66b++骨髓细胞上.
- 观察到的赔率比率 (OR) 从0.938到1.031不等,调整后的FDRp值表明了统计学意义.
结论:
- 这项研究证实了七种不同的免疫表型与患阿尔茨海默病的风险之间存在显著的关联.
- 这些发现为研究AD的潜在生物机制的研究人员提供了新的视角.
- 鉴定的免疫关联可能为开发早期的AD诊断和治疗策略铺平了道路.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.CD3333 CD3333 CD3333 CD3333 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33有因果关系的因果关系.免疫细胞是免疫细胞.门德尔的随机化更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.8K
相关概念视频
Psychoneuroimmunology: Diabetes and Cancer
29
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
29
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
